SCRIP
CITELINE COMMERCIAL

11 Dec 2022 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: US prospects for Sarepta’s DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk CEO Mads Øvlisen shares his career and life lessons.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 December 2022, including: US prospects for *Sarepta Therapeutics, Inc.*’s DMD gene therapy; looking at price increases in the US; *Eisai Co., Ltd.* plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-*Novo Nordisk A/S* CEO Mads Øvlisen shares his career and life lessons.

This and all our other podcasts are available on the Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA*" - Scrip, 6 Dec, 2022.)

(Also see "*Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List*" - Scrip, 6 Dec, 2022.)

(Also see "*Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab*" - Scrip, 2 Dec, 2022.)

SCRIP
CITELINE COMMERCIAL

(Also see "*China Winds Down 'COVID Zero' But Vaccine Fatigue, Other Worries Linger*" - Scrip, 6 Dec, 2022.)

(Also see "*Lessons From Novo Nordisk's Mads Øvlisen, The Father Of CSR*" - Scrip, 6 Dec, 2022.)

Click here to explore this interactive content online